Next Article in Journal
Tomato Leaf Curl New Delhi Virus: An Emerging Virus Complex Threatening Vegetable and Fiber Crops
Previous Article in Journal
Viruses of Microbes
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessCommunication
Viruses 2017, 9(10), 265;

A Recombinant Measles Vaccine with Enhanced Resistance to Passive Immunity

School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA
Present Address: Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA
Present Address: Process Development Department, Virus and Gene Therapy, Merck KGaA, 64293 Darmstadt, Germany
Author to whom correspondence should be addressed.
Received: 25 May 2017 / Revised: 19 September 2017 / Accepted: 19 September 2017 / Published: 21 September 2017
(This article belongs to the Section Antivirals & Vaccines)
Full-Text   |   PDF [854 KB, uploaded 22 September 2017]   |  


Current measles vaccines suffer from poor effectiveness in young infants due primarily to the inhibitory effect of residual maternal immunity on vaccine responses. The development of a measles vaccine that resists such passive immunity would strongly contribute to the stalled effort toward measles eradication. In this concise communication, we show that a measles virus (MV) with enhanced hemagglutinin (H) expression and incorporation, termed MVvac2-H2, retained its enhanced immunogenicity, previously established in older mice, when administered to very young, genetically modified, MV-susceptible mice in the presence of passive anti-measles immunity. This immunity level mimics the sub-neutralizing immunity prevalent in infants too young to be vaccinated. Additionally, toward a more physiological small animal model of maternal anti-measles immunity interference, we document vertical transfer of passive anti-MV immunity in genetically-modified, MV susceptible mice and show in this physiological model a better MVvac2-H2 immunogenic profile than that of the parental vaccine strain. In sum, these data support the notion that enhancing MV hemagglutinin incorporation can circumvent in vivo neutralization. This strategy merits additional exploration as an alternative pediatric measles vaccine. View Full-Text
Keywords: measles vaccine; infant vaccination; maternal antibodies measles vaccine; infant vaccination; maternal antibodies

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Julik, E.; Reyes-del Valle, J. A Recombinant Measles Vaccine with Enhanced Resistance to Passive Immunity. Viruses 2017, 9, 265.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top